Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Utec has made its largest initial commitment to date by backing Keio-founded Metcela, a developer of cell therapies for heart disease.

SK Biopharmaceuticals will divest a 12% stake in Arvelle, which is looking to commercialise an epilepsy drug treatment, through the acquisition.

Bristol Myers Squibb participated in a series B round for the oncology drug developer that pushed its overall funding to $168m.

The oncolytic virus therapy-based cancer drug developer raised $77m in a GV-backed series A round as it prepares to file an IND application next year.

The heart disease therapy developer completed a $12.7m round that included Alfresa, Dai-ichi Life, Sony Innovation Fund and Japan Lifeline.

Ionis Pharmaceuticals and Johnson & Johnson Innovation – JJDC were among the investors in a round that will fund development of Aro's centyrin-RNA conjugate medicines.

The Alphabet, GSK, WuXi AppTec, Johnson & Johnson, Roche and Illumina-backed genetic testing service has now raised over $870m altogether.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Today’s deal net round ups the smaller investments from across the university innovation ecosystem that have occurred over the holiday period.